EAE

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
Wednesday, March 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.

Alumis Presents Preclinical Data for Allosteric TYK2 Inhibitor A-005 at ACTRIMS

Retrieved on: 
Friday, March 1, 2024
Central nervous system, Research, EAE, Treatment, Rat, Multiple sclerosis, Allosteric regulation, CNS, Microdialysis, Patient, TYK2, Poster, Brain, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Alumis Inc., a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to transform the lives of patients with immune-mediated diseases, today announced preclinical data for A-005 at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) forum. A-005 is a potential first-in-class, brain penetrant tyrosine kinase 2 (TYK2) inhibitor being developed for the treatment of multiple sclerosis (MS), Parkinson’s Disease and other neuroinflammatory and neurodegenerative diseases, with Phase I clinical trial initiation planned in the first half of 2024.

Key Points: 
  • “Therapeutic inhibition of TYK2 has been clinically validated to treat immune-mediated diseases, but there remains a medical need for the clinical development of an allosteric TYK2 inhibitor targeting the central nervous system,” said David Goldstein, Ph.D., Chief Scientific Officer, Alumis.
  • Presented as a poster, results demonstrated A-005 to be highly potent and inhibit TYK2 pathway activation in human whole blood, PBMCs and microglial cells.
  • The data also underscored the ability of A-005 to reduce EAE clinical scores when administered prophylactically or therapeutically.
  • Data are being presented during ACTRIMS 2024 Poster Session 2 on March 1, 2024, from 6:00-7:30 pm ET, Poster Number 400.

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Retrieved on: 
Wednesday, November 1, 2023
Intellectual disability, Inflammasome, EAE, ASC, Mouse, NLRP3, Microglia, Neuroprotection, Phenotype, Inflammation, Research, Brain, Neurotoxicity, Neuroinflammation, Immunomodulation, M1, Molecular neuroscience, Multiple sclerosis, Spinal cord, Astrocyte, Disability, Therapy, Neuroscience, Super Meat Boy, MS, Central nervous system, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • Key findings showed that NLRP3 inflammasome inhibition:
    Ameliorated pathological changes in the spinal cord and neuron damage in the brain of MS mice.
  • “It is encouraging that the research published in Molecular Neurobiology substantiates our published MS data with Inflammasome ASC Inhibitor IC 100, providing support for its use as a potential therapeutic option.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.

Media.com Launches International “Road Show” To Engage With Public Relations and Business Leaders

Retrieved on: 
Tuesday, October 17, 2023
Diamond, IPRA Golden World Awards, Acquisition, Organization, Marcom, Public Relations Society of America, Marketing, EAE Business School, Reputation, PRSA, EAE, PR, Social media, Conference, Mawhinney, Film industry

At the EAE Business School in Barcelona, James Mawhinney will be guest speaker on the topic of “Business and Reputation Management: how business reputation impacts ROI.”

Key Points: 
  • At the EAE Business School in Barcelona, James Mawhinney will be guest speaker on the topic of “Business and Reputation Management: how business reputation impacts ROI.”
    Headlining the prestigious IPRA Golden World Awards for Excellence in Barcelona on October 20, 2023.
  • The Media.com network empowers users with a versatile range of text, video, and audio-based tools to express themselves and engage with their audience effectively.
  • "The road show and PR industry sponsorships give us a compelling way to engage with marketing and communications leaders, brands and experts,” said Mawhinney.
  • Discussions are also underway with various high profile public figures to join Media.com with announcements expected on this front in the coming weeks.

Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance

Retrieved on: 
Wednesday, September 6, 2023
Cognition, Rapunzel's Tangled Adventure (season 2), National academy, Human, PNAS, Microglia, Memory, Neurodegenerative disease, EAE, Prefrontal cortex, Brain, Research, NanoString Technologies, Gene expression, Multiple sclerosis, Astrocyte, Homeostasis, Harvard Medical School, Anti-CD3 monoclonal antibody, Publication, Animal, Patient, Neurology, Immune system, Mab, Mouse, Hospital, FDA, AD, Phenotype, IND, Alzheimer's disease, Hippocampus, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Brigham

Remarkably, we found this benefit occurred independent of reduction of amyloid beta plaque in the brain.

Key Points: 
  • Remarkably, we found this benefit occurred independent of reduction of amyloid beta plaque in the brain.
  • This represents a unique approach to treating Alzheimer’s disease that could also potentially be employed in combination with anti-amyloid therapy.
  • Alzheimer's disease is a neurodegenerative disease characterized by amyloid beta (Aβ) plaques, neurofibrillary tangles, and microglial activation.
  • In this study, mice were treated three times a week with intranasal anti-CD3 for five months and compared against isotype control or saline.

Ashvattha Therapeutics Presents Promising Preclinical Data on New Dendranib Nanomedicine Candidate ASH41020 at the 16th International Society of Neuroimmunology Congress (ISNI)

Retrieved on: 
Tuesday, August 22, 2023
Central nervous system, Cell death, Therapy, Macrophage, Survival, ISNI, EAE, Nanomedicine, Cell, Multiple sclerosis, CNS, MS, Microglia, Poster, Phenotype, Environment, CSF1R, International Society, Disease, Pharmaceutical industry, M1

The preclinical data were presented in a poster at the 16th International Society of Neuroimmunology Congress (ISNI) held at the Centre des Congrès Québec in Québec City, Canada, from August 21st – 24th, 2023, and accessible here .

Key Points: 
  • The preclinical data were presented in a poster at the 16th International Society of Neuroimmunology Congress (ISNI) held at the Centre des Congrès Québec in Québec City, Canada, from August 21st – 24th, 2023, and accessible here .
  • “These data build on previous studies that show our precision nanomedicine therapeutics selectively target activated cells in regions of inflammation.”
    MS is a chronic inflammatory demyelinating disorder of the central nervous system (CNS).
  • In the EAE model of MS, treatment with ASH41020 after disease onset decreased symptom severity in a dose dependent manner.
  • Collectively, these preclinical data show the anti-inflammatory and immunomodulatory potential of ASH41020.

LAPIX Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA

Retrieved on: 
Thursday, January 26, 2023
MS, Food, Multiple sclerosis, Immune system, Spectrum disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Neuro, NMOSD, EAE, MOGAD, Immune tolerance, Degenerative disease, Therapy, Pharmaceutical industry, Vaccine

BOSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology, today announced the successful outcome of its pre-IND meeting request with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • BOSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology, today announced the successful outcome of its pre-IND meeting request with the U.S. Food and Drug Administration (FDA).
  • The meeting’s objective was to achieve alignment with the FDA on LAPIX’s IND-enabling plan for its novel, first-in-class, immune tolerance restoration small molecule, LPX-TI641, under development for neuro-autoimmune indications such as multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD).
  • We also expect it to be safe enough for early and long-term use,” said Anas M. Fathallah, Ph.D., President, and Co-founder of LAPIX.
  • “The outcome of this meeting request supports LAPIX’s IND-enabling plan and we now have a path forward to the clinic.”

Abata Therapeutics Announces First Development Candidate, ABA-101, a Novel Treg Cell Therapy for the Treatment of Progressive Multiple Sclerosis

Retrieved on: 
Wednesday, December 14, 2022
General Health, Health, Other Health, Therapy, T1D, Immune system, JDRF, Third Rock Ventures, MRI, Patient, EAE, Biomarker, Science, TCR, Lightspeed Venture Partners, Biology, MS, CSO, Disease, Degenerative disease, Pathology, Pleasure, Inflammation, Clinical trial, Autoimmunity, Hope, Multiple sclerosis, CNS, Phenotype, Pharmaceutical industry, Vaccine, Regulatory T cell

Our work to date developing ABA-101 validates our approach of using TCR-targeted Treg therapies to treat autoimmune diseases.

Key Points: 
  • Our work to date developing ABA-101 validates our approach of using TCR-targeted Treg therapies to treat autoimmune diseases.
  • At ElevateBio, we enjoy collaborating with scientific innovators like Abata, helping power their novel cell and gene therapies, said Michael Paglia, M.S., chief operating officer, ElevateBio BaseCamp.
  • The hypothesis for ABA-101 as a Treg treatment for progressive MS is firmly rooted in the scientific literature.
  • ABA-101 is Abatas autologous Treg therapy in development for the treatment of progressive MS.

Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

Retrieved on: 
Tuesday, October 4, 2022
Orphan drug, ANA, Cancer, GLOBE, Acute disseminated encephalomyelitis, Optic nerve, American Neurological Association, Immunology, Adult, Nucleotide, MS, EAE, Research, Private Securities Litigation Reform Act, DCK, Deoxycytidine kinase, FDA, University of California, Los Angeles, Autoimmunity, COVID-19, Visual impairment, UCLA, Lists of diseases, ADEM, Degenerative disease, Patient, Multiple sclerosis, Optic neuritis, Central nervous system, University, DNA, Company, Pharmaceutical industry

LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).

Key Points: 
  • LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).
  • The ANA meeting is one of the largest annual gatherings of MS researchers and a key venue for presenting noteworthy neurology discoveries.
  • The work presented by Dr. Clark also has application for optic neuritis, a rare neurologic disease which affects the optic nerve causing visual impairment.
  • TRE-515 is an orally delivered first-in-class therapeutic engineered to inhibit dCK, the key enzyme in the nucleoside salvage pathway.

EQS-News: Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis

Retrieved on: 
Monday, October 3, 2022
National Academy of Sciences, MRNA, Injection, CNS, Vaccine, Lists of diseases, AstraZeneca, National academy, NASDAQ, Incidence, Advertising, Johnson & Johnson, Amyotrophy, Science, MS, EAE, Technology, Research, Disease, Nature, Psychopharmacology, Hooke, Natalizumab, Psychiatry, Brain, National, KTTA, COVID-19, Epstein–Barr virus, Ketamine, Immune system, Laboratory, ALS, Therapy, Spinal cord, NYSE, Autoimmune disease, Plasma, Multiple sclerosis, Patient, Central nervous system, Paralysis, Crohn's disease, Infection, EBV, White matter, DNA, Amyotrophic lateral sclerosis, Encephalitis, Histology, JNJ, Monkeypox, Pharmaceutical industry

Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders.

Key Points: 
  • Pasithea is a biotechnology company focused on discovering, researching and developing new and effective treatments for psychiatric and neurological disorders.
  • Pasithea recently announced encouraging preclinical results that support the efficacy of a tolerizing DNA vaccine for multiple sclerosis (MS).
  • Based on its experiments conducted with Hooke Laboratories Inc., Pasithea reported that intramuscular injections of the candidate vaccine (PAS002) delayed the onset of paralysis and reduced peak disease severity.
  • Moderna Inc. (NASDAQ: MRNA), meanwhile, has started testing the vaccine mRNA-1189 in Phase I studies but does not indicate MS, though the company believes it could potentially assist in prevention.